Search

Zi-Kang Luo,1,* Qiong-Feng Chen,2,* Xiaoqin Qu,2 Xiao-Yan Zhou2,3 1Department of Clinical Medical, The Second Clinical Medical College, Nanchang University, Nanchang 330006, People’s Republic of China; 2Department of Pathophysiology, Medical College of Nanchang University, Nanchang, Jiangxi 330006, People’s Republic of China; 3Jiangxi Province Key Laboratory of Tumor Pathogenesis and Molecular Pathology, Nanchang, Jiangxi 330006, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiao-Yan ZhouDepartment of Pathophysiology, Medical College of Nanchang University, 461 BaYi Road, Nanchang, Jiangxi 330006, People’s Republic of ChinaTel +86 791 86360556Email zhouxiaoyan@ncu.edu.cnAbstract: Phosphatidylethanolamine-binding protein 4 (PEBP4) has been found to be highly expressed in many tumors and to be closely related to the proliferation, differentiation, and metastasis of tumors. PEBP4 has also been found to be involved in many cancer-activated signaling pathways and to cause therapeutic resistance. In this study, we first reviewed the morphological structure and expression of PEBP4, then discussed the roles of PEBP4 in individualized treatment of some cancers, and finally explored the possibilities of cultivating PEBP4 as a therapeutic target.We also identified the main signaling pathways in which PEBP4 affects different cancers. It is here concluded that over-expression of PEBP4 can enhance the proliferation and metastasis of the cancer cells and the resistance to radiotherapy/chemotherapy in cancers.Keywords: PEBP4, signaling pathway, targeted therapy